Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.

doi:10.1016/j.jpedsurg.2009.07.050

Article

Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.

Journal of pediatric surgery - 1 Dec 2009

Tajiri Tatsuro, Souzaki Ryota, Kinoshita Yoshiaki, Tanaka Sakura, Koga Yuhki, Suminoe Aiko, Matsuzaki Akinobu, Hara Toshiro, Taguchi Tomoaki

Abstract excerpt

PURPOSE: The mass screening (MS) for neuroblastoma (NB) at 6 months of age in Japan was discontinued in 2004. This study assessed the risks and benefits of MS based on an analysis of NB detected before or after discontinuation of MS in Japan. METHODS: The clinical features and Brodeur's genetic t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.

Abstract excerpt

Topics

Related research